The Wren PROSTest is a 27-gene blood biopsy biomarker delivering greater than 90% accuracy in diagnosing and monitoring prostate cancer.
This study demonstrates sensitivity and specificity benefits of a blood-based multianalyte NET gene transcript measurement to detect GI tract cancer.
A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. Recent research indicates that NETest, a 51 panel multigene blood transcript analysis, is significantly more sensitive and efficient (>93%) than any single analyte assay (CgA, PST or NKA) for NET detection in a prospectively collected age and sex matched sample set of NETs and controls.
A critical requirement in neuroendocrine tumor (NET) management is a sensitive, specific and reproducible blood biomarker test. Research shows NETest was >92% accurate, while CgA was 76% accurate, PST 63% accurate and NKA 39% accurate.
This study demonstrates that a blood-based multianalyte NET gene transcript measurement of well-differentiated small intestinal and pancreatic NET disease is sensitive (94-98%) and specific, and outperforms the current monoanalyte diagnostic strategy of plasma CgA (52%) measurement.
PPGLs exhibit variable malignancy, which is difficult to determine by histopathology, amine measurements or tissue genetic analyses. Circulating NET transcript analysis is positive (100% diagnostic) in well-differentiated PCC/PGL, scores were elevated in progressive disease irrespective of mutation or biochemical activity and elevated levels were prognostic.
Current biomarkers used in broncopulmonary neuroendocrine tumor management are single analytes and have a low utility, e.g., CgA (Chromogranin A) or NSE (neuron specific enolase). Blood NET gene levels accurately identified BPNETs (100%) and differentiated these from controls, benign and malignant lung disease.
